Last week, experts with experience in China life science partnering presented their expertise in panel discussions at ChinaBio® Day; Genzyme began construction of a $100 million R&D center in Beijing; the Shanghai Institute of Biological Sciences (SIBS) won SFDA approval to produce its H1N1 vaccine; Abbott Labs was given approval for its Xience V® drug eluting stent system; China Aoxing Pharma was approved to begin a clinical trial of Tilidine/Naloxone capsules, a narcotic pain drug; LEAD Therapeutics released data on a novel glycopeptide antibiotic; Tianyin Pharma received GMP certification for its new solid dosage manufacturing facility; and China Medical Technologies (????????) announced a $30 million share buyback program. More details...
China Aoxing Pharmaceutical Company received SFDA approval to begin a clinical trial of Tilidine/Naloxone capsules, a narcotic drug for moderate to severe pain. The drug is given to alleviate cancer and post-surgical pain. China Aoxing plans to begin the clinical trial by the end of this year, and expects to receive final approval of the drug in 2011. As a Class III New Medicine, it will be given at least three years of market exclusivity protection following SFDA approval. More details...
Sinovac Biotech (????????????) received SFDA approval for its H1N1 flu vaccine; it also announced an order for 3.3 million doses of the vaccine for a stockpile that China is building; twenty CROs in Guangzhou formed a regional consortium to promote cooperation among the members; CRO Sundia MediTech (???????????????) was given the Highest Growth Potential Award by Zhangjiang Hi-Tech Park; China Aoxing Pharma (??????) filed for SFDA approval of Codeine Phosphate for cough; Sinopharm Holdings placed 20% of its upcoming $1 billion IPO in Hong Kong with eight “cornerstone” investors; and China Medical made a disappointing earnings announcement. More details...
China Aoxing Pharmaceutical Company (??????), which specializes in the strictly regulated sector of narcotic and pain medications, has submitted its application for SFDA approval of Codeine Phosphate, an oral solution for the treatment of acute moderate to severe cough. China Aoxing expects to launch this product in China in 2010, assuming the regulatory review goes well. More details...
Cheezheng Tibetan Medicine was approved to IPO on the Shenzhen exchange; Shanghai Fosun Pharma now owns 24% of Tongjitang Chinese Medicines; China Aoxing Pharma raised $5 million by selling shares; S-Evans Biosciences of Hangzhou received China rights to Cryo-Cell's menstrual stem cell technology; Shenzhen Mellow Hope Pharm will distribute a North China Pharma hepatitis B vaccine internationally; WuXi PharmaTech (????) said Q2 revenues slipped slightly; Mindray Medical (??????????) reported a 10% increase in revenues; 3SBio (??????) announced Q2 revenues rose a steady 37%; Tianyin Pharma received SFDA approvals for two new TCM products; and researchers from Institut Pasteur in Shanghai and Paris discovered new combinations of rhinoviruse genomes in Shanghai children. More details...
According to Thomson Reuters, China will be the world's leading technology innovator by 2012; the ChinaBio® Investor Forum awarded prestigious "Most Promising Company" awards to Fountain Medical and ProteLight Pharmaceutical & Biotechnology; China Aoxing Pharma received an SFDA production license for an OTC pain drug; Crucell said the SFDA released its hepatitis B vaccine for registration and quality control; China Sky One Medical (??????????) received approval from the SFDA for two new drugs; we took a deep look at China Sky One's growing product portfolio and very deep pipeline; RHEI Pharma has begun the final China clinical trial for a locally active antifungal; BioDuro announced it has been awarded full accreditation from the AAALAC; Cook Medical will open a combined distribution and customer service center in Shanghai; and China Shenghuo Pharma[More...]
China Aoxing Pharmaceutical Company was awarded an SFDA production license for Paracetamol (acetaminophen) and Caffeine Tablets, a treatment for mild to moderate pain. Although the new product will be marketed as an OTC drug, it is considered a controlled substance by the SFDA. China Aoxing is one of a relatively few companies that is licensed to manufacture narcotic and controlled substance pain medication drugs in China. China Aoxing said the company will launch the product in early 2009, once it receives GMP certification. More details... Stock Symbol: (OTCBB: CAXG)[More...]
Last week, at ChinaBio® Today, we discussed the implications of the new China offices of the US FDA; meanwhile, a China pharmaceutical product has once again caused deadly side effects; WuXi PharmaTech released weaker-than-expected financial Q3 results, while it also expanded one of its big pharma collaborations; China Aoxing Pharma said its 2008 revenues climbed 264%; China Biologic Products purchased a 35% stake in Xi'an Huitian Blood Products; Pioneer Surgical Technology signed up Bonovo Orthopedics. to distribute its products in China; Charles River Laboratories and Shanghai Explorer formally opened their preclinical facility in Shanghai; and China Sky One Medical said production started at a new subsidiary. More details... Stock Symbol: (NYSE: WX) (NSDQ: CAXG) (OTCBB: CBPO) (NYSE: CRL) (NSDQ: CSKI)[More...]
American Oriental Bioengineering (
NYSE: AOB) has generated more than its fair share of financial engineering news during the first four days of this week. On Monday, the company announced it would buy back up to $75 million of its shares.
[More...]
All News |
Breaking News |
Featured Stories